ABSTRACT-The effect of FK506 (tacrolims hydrate), an immunosuppressive agent produced by Strepto myces tsukubaensis, on crescentic-type anti-glomerular basement membrane (GBM) nephritis in rats was investigated. When rats were treated with FK506 from 1 or 20 days after the anti-GBM serum injection, FK506 inhibited the increase in urinary protein excretion. Histological observation demonstrated that FK506 suppressed glomerular alterations. In the FK506-treated rats, antibody production and rat-IgG and C3 deposits on the GBM were significantly less than those in the nephritic control group. FK506 treatment suppressed the accumulation of ED-1-positive cells, CD4-positive cells, CD8-positive cells, interleukin-2 (IL-2)-receptor-positive cells, leukocyte-function-associated antigen-1 (LFA-1)-positive cells and intercellu lar adhesion molecule-1 (ICAM-1)-expression in nephritic glomeruli. However, in the in vitro study, FK506 failed to inhibit the up-regulated ICAM-1 expression on endothelial cells in response to tumor necrosis factor (TNF)-a. On the other hand, IL-2 production from the spleen cells isolated from nephritic rats treated with FK506 was lower than that in the nephritic control rats. These results suggest that FK506 is effective against crescentic-type anti-GBM nephritis and that the antinephritic mechanisms of FK506 is due to the inhibition of intraglomerular accumulation and activation of leukocytes through the suppression of ICAM-1 expression and IL-2 production.
FK506 is a macrocyclic lactone produced by Strepto myces tsukubaensis, a soil bacterium from the Tsukuba region of Japan (1).
Recent studies have shown that FK506 has an im munosuppressive action; namely, FK506 blocks T cell ac tivation or proliferation (2-4) and suppresses graft rejec tion (5). These actions suggest that FK506 can suppress delayed-type hypersensitivity, but the exact mode of ac tion of FK506 is not known.
The potential of FK506 to suppress other immuno pathologic conditions, such as glomerulonephritis, is largely unknown, although there has been a recent report (6) that FK506 can suppress the development of spontaneous lupus-like nephropathy in susceptible mice. In those studies, FK506 was demonstrated to suppress the production of anti-DNA antibody and to prevent the de velopment of lupus nephritis by the suppression of both antibody deposition and hyperplasia of lymph nodes when it was given to susceptible mice prior to the onset of the apparent disease or after the appearance of physical evidence of the disease. On the other hand, although it has been reported that FK506 can suppress the progres sion of active Heymann nephritis (7, 8) and Masugi nephritis (8), the anti-nephritic mechanism of FK506 is unknown on these models as well. Nagamatsu et al. (9) has demonstrated that cyclosporin A suppressed the de velopment and progression of anti-glomerular basement membrane (GBM) nephritis through the inhibition of glomerular infiltration of leukocytes. It was reported that FK506 had a more potent effect than cyclosporin A in in vitro studies, reflecting their immunosuppressive effect (1, 10-12). We also found that FK506 was more effective than cyclosporin A in terms of the suppressive action on IL-2 produced by concanavalin A in mouse spleen cells (unpublished data of K. Hayashi). Therefore, FK506 is expected to exert a greater antinephritic effect than cyclo sporin A, through antinephritic mechanisms similar to cyclosporin A.
In the present report, we have shown the efficacy of FK506 in preventing the immunopathological insult of 
MATERIALS AND METHODS

Animals
Male Sprague-Dawley strain rats, weighing approxi mately 160 g (Nihon SLC, Hamamatsu), were used in all experiments. These animals were housed in an air-con ditioned room at 23 ± 1 C during the experimental period. Drugs FK506 (Fujisawa Pharm. Co., Ltd., Osaka) dissolved in ethanol with 20% Tween 80 was diluted in sterile saline at concentrations of 0.2, 0.8 or 2.0 mg/kg per 0.5 ml. Cyclosporin A (Sandoz, Tokyo) was dissolved in olive oil with 1076 ethanol at the concentration of 20 mg/kg in a volume of 1 ml per 100 mg of body weight. For the in vitro studies, FK506 was dissolved in ethanol at 1 x 102 M. Cyclosporin A was dissolved in ethanol with 20% Tween 80 at 1 x 10-2 M. H-7 (Seikagaku Kogyo Co., Ltd., Tokyo) was dissolved in RPMI 1640 at 1 x 10-2 M. Anti-cytokine neutralizing antibodies (rabbit anti-human tumor necrosis factor (TNF)-a polyclonal antibody and rabbit anti-human interleukin-1 (IL-1) ,8 polyclonal anti body) and recombinant human TNF-a were purchased from Genzyme Co., Ltd. (Cambridge, MA, USA).
Induction of crescentic-type anti-GBM nephritis
Crescentic-type anti-GBM nephritis was inducted by immunizing the rats, which had received a nephritogenic dose of rabbit anti-rat GBM (anti-GBM) serum, with rabbit f-globulin according to a slight modification of the previously reported method (13). In this experiment, rats were administered 0.9 ml/animal of anti-GBM serum into the tail vein.
The effect of test drugs was estimated by administering them from 1 day after the anti-GBM serum injection (heterologous phase) or from 20 days after the anti-GBM serum injection (autologous phases). In the experiments, 24-hr urine samples were collected, and the rats were then divided into 4 or 5 groups of 7 rats, so that the average protein content in the 24-hr urine in each group was at a similar level.
Evaluation of antinephritic effect of the test drugs
Three groups were administered subcutaneously 0.2, 0.8 or 2.0 mg/kg/day of FK506, respectively, in a volume of 0.5 ml per rat, daily from 1 or 20 days after the anti GBM serum injection to 40 days. The remaining group was administered subcutaneously or orally given the vehi cle (saline or olive oil) instead of test drugs and served as the nephritic control. In addition, a nontreated (normal) group was used for comparison with the nephritic groups.
Determinations of urinary protein and plasma choles terol
The 24-hr urine sample was obtained by keeping each animal in an individual metabolic cage for 24 hr. The urinary protein excretion was determined by the method of Kingsbury et al. (14) and expressed as mg/24-hr urine.
Blood was drawn from eyeground of conscious animal with a heparinized hematocrit capillary. The cholesterol content was determined with a commercial assay kit (Determina TC-5; Kyowa Medex Co., Ltd., Tokyo) (15).
Measurement of plasma antibody against r-G
The measurement of rat anti-rabbit IgG antibody was performed by enzyme-linked immunosorbent assay (ELISA) (13).
Assessment of histopathological parameters
For the light microscopic study, kidneys were isolated from rats anesthetized with pentobarbital (50 mg/ml), then fixed in 10% formalin in 0.01 M phosphate buffer saline (PBS), pH 7.4, and dehydrated by immersing the tissues stepwise into various concentrations of ethyl alco hol from low to high. The tissues were then embedded in paraffin and sectioned into 2 to 3-pm-thick slices. In the studies of crescentic-type anti-GBM nephritis, the sections were stained with Masson's trichrome. Crescent formation, adhesion of Bowman's capsule to the capil lary wall (adhesion) and fibrinoid necrosis in the glomeruli were observed under a light microscope. For assessing these parameters, an equatorial cross section was selected by random sampling methods. Fifty glomeruli/section were observed, and the appearance rate of crescent for mation, adhesion and fibrinoid necrosis are expressed as the percentages of the glomeruli (incidence) having these morphological alterations as the previously reported method (13). For assessing hypercellularity, an equatorial cross-section was selected by a random sampling method. The number of nuclei (including the nuclei of glomerular cells and exudative leukocytes) was counted and the results are expressed as the mean number per glomerular cross section (G.C.S.) in 30 glomeruli/section.
The evaluation was performed by a different person in blind fashion.
Immunohistochemistry
In tissues for immunoenzymatic staining of rat-IgG, leukocytes, intercellular adhesion molecule-1 (ICAM-1), proliferating cell nuclear antigen (PCNA, a marker for cell proliferation) and mesangial area (Thy1.1-positive area), the paraffin sections were cut as described above, and the sections were labeled with monoclonal antibodies (mAbs) as previously described (16 Additionally, for rat-C3, the cryostat sections were in cubated peroxidase-conjugated goat-IgG fraction to rat complement C3 with DAB (Cappel, West Chester, PA, USA) after washing in PBS. The cells were suspended in the culture medium (MCDB131 with 2% fetal bovine serum (FBS), 10 pg heparin/ml, 10 pg endothelial cell growth sup plement/ml, 10 pg epidermal growth factor/ml, 1 pg hydrocortisone/ml, 50 pg gentamicin/ml, 0.251 cg am photericin B/ml) (Curabou) and grown in 75 cm2 tissue culture flasks (Becton Dickinson, Franklin Lakes, NJ, USA). The culture medium was changed twice weekly. HUVECs were trypsinized when subconfluent, resuspended in the culture medium, and either seeded into new culture flasks or collagen-coated, 96-well-plates. HUVECs were used from passage 3 6.
Cell ELISA: HUVECs (1 x 104 cells/well) were seeded into 96-well, flat-bottomed type-I-collagen-coated plates (Sumitomo Bakelite Co., Ltd., Tokyo) in 100 p1 of M199 (Nissui Pharmaceutical Co., Ltd., Tokyo) and allowed to reach subconfluency (approximately 105 cells/well). When HUVECs were subconfluent, 100 pl of the medium from each well was removed, and then 50 pl of the RPMI 1640 or various concentrations of FK506, cyclosporin A, H-7 or anti-cytokine antibodies was added to the ap propriate wells. Then 50 111 of recombinant human TNF a (final concentration: 100 U/ml) or medium were added to each appropriate well to yield a final volume of 100 pl/well. The cultured cells were incubated for 20 hr at 37V in 5010 CO2-95070 air. The cell monolayers were washed twice with Hanks' balanced salt solution (HBSS) (Sanko Junyaku Co., Ltd., Tokyo) and then fixed with 1 % paraformaldehyde for 15 min at room temperature. After washing the fixed HUVECs three times with HBSS, the unbound sites were blocked by casein (Block A®; Yukizirushi Co., Ltd., Sapporo) diluted in HBSS and incubated at 37V for 1 hr in 5% CO2-95070 air. The blocking solution was removed from the plates by aspi ration. A total of 100 pl of anti-human ICAM-1 mAb, which was kindly supplied by Dr. Yagita (Department of Immunology, Juntendo University School of Medicine, Tokyo) was added into each well and the plates were in cubated at 37V for 1 hr in 5 % C02-95% air. Anti-hu man ICAM-1 mAb was removed by aspiration from the plates and the culture wells were washed three times with HBSS. After the last washing, 100 p1 of a 1/2000 dilution of the secondly antibody (goat anti-mouse IgG (H+L) horseradish peroxidase conjugate; Bio-Rad Lab. Co., Ltd., Richmond, CA, USA) in RPMI 1640 was added into each well. The plates were then incubated for 1 hr at 37V in 5 % C02-95% air. After washing with PBS, o-phenylene-deamine development was determined by measuring the optical density at 490 nm with a Microplate reader (model 3550 Microplate reader; Bio-Rad Lab. Co., Ltd.).
Measurement of IL-2 activity
Cell line: CTLL-2 (cytotoxic T cell, No. TIB 214; American Type Culture Collection, Rockville, MD, USA) was cultured in MEDIA II (Immuno-Biological Lab., Fuzioka) with 10% FBS (Gibco, Grand Island, NY, USA), penicillin (100 pg/ml) (Sigma, St. Louis, MO, USA), streptomycin (100 pg/ml) (Sigma), glutamine (300 pg/ml) (Gibco) and 20% rat IL-2 (Immuno-Biological Lab.). Cultured cells were maintained in a humidified incubator at 37V in 5% CO2-95010 air. They were pas saged every 4 days.
Preparation of spleen cell suspension: The spleens were aseptically removed from normal, nephritic control or FK506 or cyclosporin A-treated rats, and the spleen cells were gently dissociated in ice-cold RPMI 1640. The cell suspensions were centrifuged, and the pellets were depleted of contaminating red cells by treatment with ACT buffer (tris-HCl buffer with 0.83% NH4C1). After washing, the spleen cells were resuspended in complete culture medium (RPMI 1640 with 10% FBS, penicillin (100 pg/ml), streptomycin (100 pg/ml), glutamine (300 pg/ml), 2-ME (5 x 10-5 M)) at 1 X 107 cells/ml.
Spleen cell culture and IL-2 induction: Cultures were set up in flat-bottom, 48-well plates (Costar, Cambridge, MA, USA). Each well received 100 pl of cell suspension at 1 x 107 cells/ml. The plates were incubated at 371C in 5076 C02-95% air for 24-36 hr. Measurement of IL-2 activity: Supernatants from non stimulated spleen cells were collected and centrifuged at 220 x g for 5 min to remove the spleen cells from the supernatants. The assessment of IL-2 activity was per formed as described by Gills et al. (17) with the use of the IL-2-dependent cell line (CTLL-2). 
RESULTS
Effect of FK506 on crescentic-type anti-GBM nephritis Urinary protein excretion (Fig. 1) : When the treat ment of FK506 was started from the day after the anti GBM serum injection (heterologous phase), the first significant suppression of urinary protein was observed in 10 days at 2.0 mg/kg, s.c.; in 20 days at 0.8 mg/kg, s.c.; and in 40 days at 0.2 mg/kg, s.c. (Fig. 2, a-c; Fig. 3 ) and autologous phases (data not shown)) inhibited the incidence of crescentic formation, adhesion and fibrinoid necrosis in the glomeruli. The lesion of cyclosporin A-treated nephritic rats (from auto logous phase) was also less than those of the nephritic control rats (data not shown). On the 15th day, the number of nuclei (total cells), PCNA-positive cells (proliferating cells) and the amount of Thyl.1-positive area (mesangial area) in the glomeruli were significantly greater in the nephritic control rats than in the normal rats (Table 1; Fig. 2, g-i) . FK506 markedly suppressed the increases in total numbers of cells (hyper cellularity), numbers of proliferated cells and mesangial area by 67010, 72% and 100%, respectively (Table 1; Fig.  2, g-i) . Cyclosporin A also suppressed the increase in total cell numbers and mesangial area by 34% and 100010, respectively. Fig. 2 ): Nephritic rats had markedly accelerated antibody production. The accelerated antibody production was suppressed with FK506 (0.2, 0.8 and 2.0 mg/kg) from the heterologous phase on days 15 and 40 (Table 2 ). However, it was not affected by FK506 from the autologous phase (data not shown).
The deposits of rat-IgG and C3 on the GBM were ob served in nephritic control rats, but not in normal rats. FK506 (0.8 and 2.0 mg/kg) from the heterologous phase abrogated rat-IgG and C3 deposition on the GBM (Table  2 ; Fig. 2, d-f) . Glomerular accumulation of leukocytes (Fig. 4) : Nephritic rats in two groups were given, once daily, FK506 at 0.8 mg/kg, s.c., a dose that has shown a marked antinephritic action on the early stage of crescentic-type anti-GBM nephritis in rats, and cyclosporin A at 20 mg/kg p.o., respectively, from 1 day after the anti-GBM serum injection to day 5 or 15. /kg, p.o.) . G.C.S.: glomerular cross section. Each column denotes the mean±S.D. of 5 rats. *P<0 .05, **P<0.01, compared to the nephritic control rats.
shown). As shown on Table 3 , FK506 and cyclosporin A failed to abrogate TNF-a induced ICAM-1 expression on the surface of HUVECs at a nontoxic concentration. On the other hand, H-7 (1 x 10-5-1 x 10-7 M) prevented ICAM 1 expression of HUVECs in response to TNF-a for 20 hr.
Effect of FK506 on IL-2 production from spleen cells of nephritic rats (Fig. 7) : Spontaneous IL-2 production in cultures of normal rat spleen cells was 213 ± 52.8 units/ml. In contrast, on day 5 after the anti-GBM serum injection, the isolated spleen cells of the nephritic control rats had augmented IL-2 production (604.7± 120.0 units/ml). When nephritic rats were treated with FK506 (0.8 mg/kg, s.c.), the IL-2 production was abrogated in the isolated spleen cells. The suppression of IL-2 produc tion by cyclosporin A was as potent as that by FK506. (Fig. 1) ; 2) prevention of progressive histological damage including crescent for mation (Figs. 2 and 3) ; 3) inhibition of autologous anti body (rat anti-rabbit IgG antibody) production and prevention of deposition of autologous antibody and rat C3 on the GBM (Table 2 and Several studies showed that FK506 suppressed the anti body production against autologous and heterologous antigen (21 -23). In these studies, FK506 inhibited the anti-rabbit IgG antibody production when FK506 treat ment was carried out from the heterologous phase (Table  2 and Fig. 2) . However, there has been no report showing the direct inhibitory effect of FK506 on B cells, and anti body production has not been affected by treatment with FK506 from the autologous phase in which the anti body level against rabbit IgG had been elevated in this experiment (data not shown). From the experiments using polyclonal B cell activators and pokeweed mitogen, Suzuki et al. (24) reported that the suppressive effects of FK506 on the antibody production could be due to the interference of interactions between T cells and B cells or macrophages. It is considered likely that FK506 inhibits antibody production through the suppression of the signal from T cells to B cells. Antigen-specific immuno suppression by FK506 was also suggested in Heymann nephritis (8). We also found that FK506 suppressed the induction and progression of accelerated passive Heymann nephritis (unpublished data of K. Hayashi et al.).
On the other hand, we previously reported that the anti platelet agent dipyridamole suppressed urinary protein excretion and histological changes, but not antibody production against rabbit IgG, in this model (13). There fore, it is suggested that the inhibition of antibody production is one of the antinephritic actions of FK506 and is not the result of the anti-nephritic action of FK506.
In vitro studies showed that FK506 inhibited the production of IL-2 (25) and affected an early stage of T cell activation (26) through the inhibition of the serine/threonine phosphatase, so-called calcineurin, the target for FK506-FK binding protein complexes (27). We also observed that FK506 at 10-6-10-9 M inhibited the IL-2 production from isolated mouse spleen cells stimu lated by concanavalin A by 87-99% (data not shown). It has been reported that IL-2 production in peripheral blood mononuclear cells increase in nephritic patients 32) . In the present study, FK506 inhibited the basal production of IL-2 from the isolated spleen cells of nephritic rats (Fig. 7) and sup pressed the accumulation of IL-2-receptor-positive cells, activated T cells, in nephritic glomeruli in this model (Fig.  4) . Taking these results together, we consider that the anti-nephritic action of FK506 is partly due to the sup pressed accumulation of leukocytes, including IL-2 receptor-positive cells, in the nephritic glomeruli through the inhibition of T cell proliferation mediated by sup pression of IL-2 production.
We further investigated the mechanism by which FK506 inhibits the accumulation of leukocytes in nephritic glomeruli. Recently, with respect to the de velopment of experimental and human nephritis, it has been reported that the up-regulation of ICAM-1 expres sion was observed in glomeruli (33), and treatment of anti ICAM-1 or LFA-1 antibody suppressed the renal in jury (34, 35). FK506 inhibited the accumulation of LFA 1-positive cells and the up-regulation of ICAM-1 expres sion in the nephritic glomeruli (Figs. 5 and 6). However, in the in vitro study, FK506 and cyclosporin A failed to abrogate the TNF-a-induced ICAM-1 expression on the surface of cultured endothelial cells (Table 3) . Moreover, FK506 and cyclosporin A did not inhibit the inflamma tory cytokine-mediated ELAM-1 and VCAM-1 expres sions on HUVECs (data not shown). Yard et al. (36) reported that FK506 and cyclosporin A inhibited the TNF-a production by cultured human proximal tubular cells in response to IL-la. In other studies by Nguyen et al. (37), it has been shown that cyclosporin A inhibits TNF-a production in murine monocytes. Several reports have demonstrated that TNF-a is produced by intrinsic glomerular cells (38, 39) and participate in the recruit ment of inflammatory cells in the glomeruli and in the progression of nephritis. Therefore, it has been consi dered that the decline in glomerular ICAM-1 expression was associated with an inhibition of TNF-a production in rats treated with FK506 or cyclosporin A. These data suggest that the antinephritic action of FK506 is, at least in part, due to the reduced amount of glomerular influx of leukocytes through the secondary inhibition of ICAM 1 expression by the inhibited production of TNF-a in the nephritic glomeruli.
In the present studies, FK506 markedly suppressed the increase in mesangial area (Table 1 and Fig. 2) . Moreover, the increase of total cells (hypercellularity) and proliferating cell numbers, including mesangial cells, were suppressed by FK506 in nephritic glomeruli (Table  1) . Glomerular cell proliferation, namely, the increase in the Thyl.l-positive area and PCNA-positive cells, is characteristic of crescentic-type anti-GBM nephritis (13). Musso et al. (40) has demonstrated that IL-2 induces IL-6 production in human monocytes. It has been reported that IL-6 transgenic mouse excretes urinary protein, causing the progression of mesangial proliferative glomerulonephritis (41) . Moreover, in both in vivo and in vitro studies, recombinant IL-6 induced the growth of rat mesangial cells (42) (43) (44) . These findings suggest that the suppressed glomerular cell proliferation by FK506 is due to the inhibition of IL-6 through the inhibition of IL-2 production.
In 
